Search results for "phosphonate"

showing 10 items of 372 documents

Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab.

2014

Dear Editor, The paper by Henry et al. published by Supportive Care in Cancer comparing efficacy of denosumab versus zoledronic acid in patients with bone metastases of advanced solid tumours [1] comes to integrate the original reports of three pivotal large randomized phase 3 trials [2–4], the publication by Saad et al. about osteonecrosis of the jaw (ONJ) in those three trials [5], and the combined outcome analysis by Lipton et al. [6]. Henry et al. [1] reported outcomes of the single trial conducted on patients with solid tumours (except breast or prostate cancers, object of other two trials) [2, 3], excluding patients with multiple myeloma: This ad hoc analysis confirmed the superiority…

MaleOncologymedicine.medical_specialtyBevacizumabONJ renal cell cancerBone NeoplasmsAntibodies Monoclonal HumanizedPazopanibSettore MED/28 - Malattie OdontostomatologicheNeoplasmsInternal medicinemedicineHumansBone ResorptionEverolimusBone Density Conservation AgentsDiphosphonatesSunitinibbusiness.industryImidazolesmedicine.diseaseTemsirolimusZoledronic acidDenosumabOncologyFemalebusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Dental extraction following zoledronate, induces osteonecrosis in rat´s jaw

2017

Background Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) is clinically characterized by the presence of exposed bone in the oral cavity that persists for more than eight weeks. Previous attempts to establish an animal model have not sufficiently considered disease features. Our aim was to establish an inexpensive and replicable animal model that develops BRONJ in a short time. Material and Methods Thirty-two male Wistar rats were randomly divided into two groups: control and experimental. In the experimental group, we administered 0.06mg/kg intraperitoneal dose of zoledronic acid (ZA) 7 and 14 days prior to maxillary second molar extraction. At two, four and six weeks after tooth …

MalePathologymedicine.medical_specialtymedicine.medical_treatmentMaxillary second molarH&E stainZoledronic AcidSequestrumRandom Allocation03 medical and health sciencesPostoperative Complications0302 clinical medicineTrichromemedicineAnimalsRats WistarGeneral DentistryOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchImidazoles030206 dentistry030224 pathologymedicine.disease:CIENCIAS MÉDICAS [UNESCO]RatsDisease Models AnimalZoledronic acidOtorhinolaryngologyDental extractionMaxillaTooth ExtractionUNESCO::CIENCIAS MÉDICASBisphosphonate-Associated Osteonecrosis of the JawSurgeryOsteonecrosis of the jawbusinessmedicine.drug
researchProduct

Short-term effect of zoledronic acid upon fracture resistance of the mandibular condyle and femoral head in an animal model

2013

Objective: The aim of this study was to compare the effects in terms of resistance to fracture of the mandibular condyle and femoral head following different doses of zoledronic acid in an animal model. Study design: A total of 80 adult male Sprague-Dawley rats were included in a prospective randomized study. The animals were randomly divided into four groups of 20 rats each. Group 1 (control) received sterile saline solution, while groups 2, 3 and 4 received a accumulated dose of 0.2 mg, 0.4 mg and 0.6 mg of zoledronic acid, respectively. The animals were sacrificed 28 days after the last dose, and the right hemimandible and the right femur were removed. The fracture strength was measured …

MaleTime FactorsDentistryOdontologíaZoledronic AcidCondyleRats Sprague-DawleyFemoral headAnimal modelMandibular FracturesmedicineAnimalsFemurTerm effectGeneral DentistryOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesHip Fracturesbusiness.industryImidazolesMandibular CondyleMandibleFemur Head:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludRatsDisease Models AnimalZoledronic acidmedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASFracture (geology)Research-ArticleSurgerybusinessmedicine.drug
researchProduct

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

2017

Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…

MalebisphosphonateTime Factorsmedicine.medical_treatmentOsteoporosis0302 clinical medicineRisk Factors80 and overosteoporosijaw osteonecrosiAged 80 and overBone Density Conservation AgentsDiphosphonatesjaw osteonecrosisjaw osteonecrosis bisphosphonates breast cancer multiple myeloma prostate cance osteoporosisIncidenceIncidence (epidemiology)Otorhinolaryngology2734 Pathology and Forensic MedicineMiddle Agedprostate cancermultiple myeloma030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleAdultmedicine.medical_specialty2734Drug Administration SchedulePathology and Forensic Medicine03 medical and health sciencesbreast cancerbisphosphonates; breast cancer; jaw osteonecrosis; multiple myeloma; osteoporosis; prostate cancer; Adult; Aged; Aged 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Otorhinolaryngology; 2734; Pathology and Forensic Medicine; Dentistry (all)Internal medicinemedicineHumansBisphosphonates; Breast cancer; Jaw osteonecrosis; Multiple myeloma; Osteoporosis; Prostate cancer; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)prostate canceAdverse effectGeneral DentistrybisphosphonatesAgedProportional Hazards ModelsRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawbusiness.industryProportional hazards modelRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseosteoporosisSurgeryCross-Sectional StudiesOtorhinolaryngologyMultivariate AnalysisDentistry (all)businessOsteonecrosis of the jaw
researchProduct

Physiology of the aging bone and mechanisms of action of bisphosphonates.

2011

Fragility fractures, a major public health concern, are expected to further increase due to aging of the world populations because age remains a cardinal, independent determinant of fracture risk. With aging the balance between bone formation and resorption during the remodeling process becomes negative, with increased resorption and reduced formation. Bisphosphonates (BPs) are widely prescribed anti-resorptive agents that inhibit osteoclasts attachment to bone matrix and enhance osteoclast apoptosis. BPs can be divided into nitrogen-containing (N-BPs) and non-nitrogen-containing BPs (non-N-BPs). Both classes induce apoptosis but they evoke it differently. Several studies have examined the …

Malemedicine.medical_specialtyAgingSettore MED/09 - Medicina Internamedicine.medical_treatmentOsteoporosisurologic and male genital diseasesBone resorptionBone and BonesBone remodelingOsteoclastInternal medicinemedicineHumansCellular SenescenceBONE BONE TURNOVER FRAGILITY FRACTURES AGING BISPHOSPHONATESOsteoblastsBone Density Conservation AgentsDiphosphonatesbusiness.industryBone metastasisOsteoblastBisphosphonatemedicine.diseaseEndocrinologymedicine.anatomical_structureOsteocyteFemaleBone RemodelingGeriatrics and GerontologybusinessGerontologyhormones hormone substitutes and hormone antagonistsBiogerontology
researchProduct

The use of zoledronic acid in patients with bone metastases from prostate carcinoma: Effect on analgesic response and bone metabolism biomarkers

2005

Zoledronic acid is a bisphosphonate that is effective in the treatment of complications of metastatic bone disease. We have carried out a perspective study on 24 consecutive patients with prostate cancer metastatic to bone to verify the effect of zoledronic acid on analgesic response and a possible relationship with the levels of bone metabolism biomarkers. Eligibility for this study required prostate cancer patients with metastatic bone disease and pain not controlled by analgesics. Patients were excluded from the study if they were receiving cytotoxic chemotherapy or radiation therapy within three months. Eighteen patients (75%) were considered responder to acid zoledronic, only 6 patient…

Malemedicine.medical_specialtyBone diseasemedicine.medical_treatmentPainBone NeoplasmsGastroenterologyBone resorptionBone remodelingProstate cancerzoledronic acidInternal medicinemedicineHumansPharmacology (medical)Bone ResorptionInfusions Intravenousbone metastaseAgedPain MeasurementPharmacologyBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesProstatic NeoplasmsMiddle AgedBisphosphonatemedicine.diseaseprostate cancerSurgeryRadiation therapyBone Density Conservation AgentsInfectious DiseasesZoledronic acidOncologybone metabolism biomarkerbusinessBiomarkersmedicine.drug
researchProduct

Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures

2012

There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized. INTRODUCTION: The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ. METHODS: An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case-control study within a cohort of individuals aged 55+ years old, who w…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismONJDentistryOsteoporosis; fractures; biphosphonatesAdministration OralBisphosphonates Nested case–control study Osteonecrosis of the jaw Osteoporotic fracturesOSTEPOROSISRisk AssessmentAssociationADMINSTRATIVE DATABASESnested case-control studySettore MED/28 - Malattie OdontostomatologicheClaims dataMedicineHumansnested case-control study; osteoporotic fractures; osteonecrosis of the jaw; bisphosphonatesWomenbisphosphonatesAgedSecondary preventionAged 80 and overOral bisphosphonatesBone Density Conservation AgentsDiphosphonatesbusiness.industryMiddle Agedmedicine.diseaseOral BisphosphonateNecrosiosteonecrosis of the jawItalyClaims DataCase-Control StudiesOrthopedic surgeryBisphosphonates; Osteonecrosis of the jaw; Osteoporotic fractures; Nested case-control studyBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgeryProfileBisphosphonate therapyMedical Record LinkagebusinessOsteonecrosis of the jawOsteoporotic Fractures
researchProduct

Bisphosphonate-related osteonecrosis of the jaws (Bronj).

2011

Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is an extremely therapy resistant osteomyelitis-like disease exclusively involving the jaw bones of patients in treatment with bisphosphonates (BPs). Objectives: The aim of this study was to evaluate the radiological and clinical findings and management of 51 patients with BRONJ diagnosed from 2004 to 2009 in our Reference Center. Study Design: A prospective study was performed. The patients were examined every 2-6 months, depending on their clinical conditions. Outcome variables were the resolution of symptoms, persistence of bone exposure and / or fistula and the status of the lesional mucosa. Results: The higher prevalence of the d…

Malemedicine.medical_specialtyFistulamedicine.medical_treatmentOdontologíaOsteotomySequestrummedicineHumansProspective StudiesProspective cohort studyGeneral DentistryPathologicalAgedBisphosphonate-associated osteonecrosis of the jawOral Medicine and Pathologybusiness.industryBisphosphonatemedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludCurettageSurgeryOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleResearch-ArticlebusinessFollow-Up StudiesMedicina oral, patologia oral y cirugia bucal
researchProduct

A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid…

2017

Background The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. Material and Methods This 5-year retrospective longitudinal study included all consecutive oncological patients who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neoplasms. Results Of the 156 patients enrolled in the study, 17 developed ONJ (10.89%). At the multivariate analysis, severe periodontal disease (P=0.025), tooth extraction (P<0.0001) and starting the preventive dental program af…

Malemedicine.medical_specialtyLongitudinal studyTime FactorsBone NeoplasmsZoledronic Acid03 medical and health sciences0302 clinical medicinestomatognathic systemRisk FactorsmedicineHumansIn patientLongitudinal StudiesGeneral DentistryAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ResearchIncidenceImidazolesRetrospective cohort study030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseMedically compromised patients in DentistrySurgeryBone Density Conservation Agentsstomatognathic diseasesZoledronic acidOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Association between periodontal disease and prostate cancer: a systematic review and meta-analysis

2021

Background Periodontal disease is a chronic infectious disease caused by bacterial infection which may lead to various systematic diseases. Recently, increasing studies have explored the correlation of periodontal disease with the risk of prostate cancer. However, the findings were inconsistent. Hence, this study aims to investigate the association between periodontal disease and the risk of prostate cancer by a meta-analysis. Material and Methods PubMed, EMBASE, and Cochrane were searched for publications up to July 17, 2020. Cohort and case-control studies evaluating the risk of prostate cancer in patients with periodontal disease were included. A fixed or random-effect model was used to …

Malemedicine.medical_specialtyMEDLINEReviewCohort Studieszoledronic acid03 medical and health sciencesProstate cancer0302 clinical medicinePeriodontal diseaseRisk FactorsInternal medicineHumansMedicinePeriodontologyIn patientbisphosphonatesGeneral DentistryPeriodontal DiseasesUNESCO:CIENCIAS MÉDICASbusiness.industryProstatic Neoplasmsdenosumab030206 dentistrymedicine.diseaseConfidence intervalosteonecrosis of the jawOtorhinolaryngologyCase-Control StudiesMeta-analysisRelative riskCohortincidenceSurgerybusinessantiangiogenic drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct